Report Summary - The report lists the top ten convertible bonds for August 2025, providing detailed information about each bond, including issuer profiles, financial data, and company highlights [16][25][37] Company Highlights 1. Zhongte Convertible Bond - The company is a globally leading specialized special steel material manufacturer with a production capacity of approximately 20 million tons of special steel materials per year. It has a comprehensive strategic layout along the coastal and riverside areas [16]. - In 2024, its operating income was 109.203 billion yuan (YoY -4.22%), and the net profit attributable to the parent company was 5.126 billion yuan (YoY -10.41%). In Q1 2025, the operating income was 26.84 billion yuan (YoY -5.59%), and the net profit attributable to the parent company was 1.384 billion yuan (YoY +1.76%) [16]. - Company highlights include being one of the world's most comprehensive special steel enterprises in terms of variety and specifications, having a complete industrial chain, and actively seeking external expansion opportunities [17]. 2. Shanlu Convertible Bond - The company's main business is road and bridge engineering construction and maintenance, and it actively expands into other fields. It has a complete business and management system and can provide one - stop comprehensive services [25]. - In 2024, its operating income was 71.348 billion yuan (YoY -2.3%), and the net profit attributable to the parent company was 2.322 billion yuan (YoY +1.47%). In Q1 2025, the operating income was 9.764 billion yuan (YoY +1.95%), and the net profit attributable to the parent company was 249 million yuan (YoY +1.89%) [25]. - Company highlights include having the concept of "China - Special Valuation," potential improvements in the balance sheet and order volume in the context of debt resolution, expected benefits from regional infrastructure plans, and seizing opportunities under the Belt and Road Initiative [26]. 3. Hebang Convertible Bond - The company has advantages in resource reserves and product diversification, covering the chemical, agricultural, and photovoltaic industries [37]. - In 2024, its operating income was 8.547 billion yuan (YoY -3.13%), and the net profit attributable to the parent company was 31 million yuan (YoY -97.55%). In Q1 2025, the operating income was 1.726 billion yuan (YoY -13.68%), and the net profit attributable to the parent company was 13 million yuan (YoY -57.99%) [37]. - Company highlights include significant contributions from phosphate mines and stable profitability of salt mines, as well as high - margin liquid methionine production [38]. 4. Aima Convertible Bond - The company is a leading enterprise in the electric two - wheeler industry, with self - developed and produced products sold through dealers [47]. - In 2024, its operating income was 21.606 billion yuan (YoY +2.71%), and the net profit attributable to the parent company was 1.988 billion yuan (YoY +5.68%). In Q1 2025, the operating income was 6.232 billion yuan (YoY +25.82%), and the net profit attributable to the parent company was 605 million yuan (YoY +25.12%) [47]. - Company highlights include potential benefits from government subsidies, expected policy support after the implementation of new national standards, and room for improvement in gross margin [48]. 5. Industrial Convertible Bond - The company is one of the first joint - stock commercial banks in China and has evolved into a modern financial service group [57]. - In 2024, its operating income was 212.226 billion yuan (YoY +0.66%), and the net profit attributable to the parent company was 77.205 billion yuan (YoY +0.12%). In Q1 2025, the operating income was 55.683 billion yuan (YoY -3.58%), and the net profit attributable to the parent company was 23.796 billion yuan (YoY -2.22%) [57]. - Company highlights include stable growth in net interest income, stable asset quality, and continuous expansion of scale and customer base [58]. 6. Youfa Convertible Bond - The company is the largest welded steel pipe R & D, production, and sales enterprise in China, with a wide range of products used in multiple fields [70]. - In 2024, its operating income was 54.822 billion yuan (YoY -10.01%), and the net profit attributable to the parent company was 425 million yuan (YoY -25.46%). In Q1 2025, the operating income was 11.402 billion yuan (YoY +6.06%), and the net profit attributable to the parent company was 133 million yuan (YoY +9680.17%) [70]. - Company highlights include national layout and leading position in the industry, active exploration of overseas markets, and high - dividend distribution [71]. 7. Chongqing Bank Convertible Bond - The company is an early local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, with a wide range of business scopes [82]. - In 2024, its operating income was 13.679 billion yuan (YoY +3.54%), and the net profit attributable to the parent company was 5.117 billion yuan (YoY +3.8%). In Q1 2025, the operating income was 3.581 billion yuan (YoY +5.3%), and the net profit attributable to the parent company was 1.624 billion yuan (YoY +5.33%) [82]. - Company highlights include the development opportunities brought by the Chengdu - Chongqing Twin - City Economic Circle strategy, stable growth of asset scale, and active adjustment of credit strategies according to national policies [83]. 8. Tianye Convertible Bond - The company is a leading enterprise in the chlor - alkali chemical industry in China, with an integrated circular economy industrial chain [94]. - In 2024, its operating income was 11.156 billion yuan (YoY -2.7%), and the net profit attributable to the parent company was 68 million yuan (YoY +108.83%). In Q1 2025, the operating income was 2.417 billion yuan (YoY +8.17%), and the net profit attributable to the parent company was - 17 million yuan (YoY +89.97%) [94]. - Company highlights include relatively stable production costs of caustic soda flakes and plans to increase dividend frequency and advance coal mine projects [95]. 9. Huayuan Convertible Bond - The company focuses on building a complete vitamin D3 upstream - downstream industrial chain and aims to become a world - leading producer of related products [105]. - In 2024, its operating income was 1.243 billion yuan (YoY +13.58%), and the net profit attributable to the parent company was 309 million yuan (YoY +60.76%). In Q1 2025, the operating income was 326 million yuan (YoY -1.18%), and the net profit attributable to the parent company was 97 million yuan (YoY +5.5%) [105]. - Company highlights include leading products in the market, smooth progress of project construction, and expansion into other vitamin product categories [106]. 10. Yushui Convertible Bond - The company is the largest integrated water supply and drainage enterprise in Chongqing, with a stable monopoly position in the local market [116]. - In 2024, its operating income was 6.999 billion yuan (YoY -3.52%), and the net profit attributable to the parent company was 785 million yuan (YoY -27.88%). In Q1 2025, the operating income was 1.652 billion yuan (YoY +8.66%), and the net profit attributable to the parent company was 237 million yuan (YoY +28.91%) [116]. - Company highlights include high market share, continuous expansion of business scope, and effective cost control through intelligent applications [117].

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-022 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于 2025 年第二季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 2、2025年第二季度，共有70张"花园转债"完成转股（票面金额共计人民币7,000.00 元），合计转成517股"花园生物"股票（证券代码：300401）。 3、截至2025年第二季度末，"花园转债"剩余债券张数为11,760,191张，剩余票面 总额为人民币1,176,019,100.00元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，浙江花园生物医药股份有限公司（以 下简称"公司"）现将2025年第二季度可转换公司债券（以下简称"可转债"）转股及 公司股份变化情况公告如下： 一、可转换公司债券基本情况 1、"花园转债"（债券代码：123178）转股 ...

Report Overview - The report presents the top ten convertible bonds for July 2025, along with an analysis of the issuing companies [1][2][11] Company Summaries 1. Zhongte Convertible Bond (Zhongte Zhuanzhai) - Bond Rating: AAA; 6 - month - end closing price: 109.399 yuan; Conversion premium rate: 108.66%; PE - TTM of the underlying stock: 11.5 [5][11] - Company is a global leader in special steel manufacturing with a production capacity of about 20 million tons. It has a complete industrial chain and multiple production bases [11][12] - In 2024, revenue was 109.203 billion yuan (down 4.22% YoY), net profit attributable to shareholders was 5.126 billion yuan (down 10.41% YoY). In Q1 2025, revenue was 26.84 billion yuan (down 5.59% YoY), net profit attributable to shareholders was 1.384 billion yuan (up 1.76% YoY) [11] - Company highlights: largest variety - specification range, leading cost - control, and potential expansion through asset injection [12] 2. Shanlu Convertible Bond (Shanlu Zhuanzhai) - Bond Rating: AAA; 6 - month - end closing price: 113.766 yuan; Conversion premium rate: 50.91%; PE - TTM of the underlying stock: 3.9 [5][20] - Company focuses on road and bridge construction and maintenance, with a comprehensive business system [20] - In 2024, revenue was 71.348 billion yuan (down 2.3% YoY), net profit attributable to shareholders was 2.322 billion yuan (up 1.47% YoY). In Q1 2025, revenue was 9.764 billion yuan (up 1.95% YoY), net profit attributable to shareholders was 0.249 billion yuan (up 1.89% YoY) [20] - Company highlights: state - owned background, potential in debt - resolution, local infrastructure opportunities, and overseas expansion [21] 3. Jintong Convertible Bond (Jintong Zhuanzhai) - Bond Rating: AA+; 6 - month - end closing price: 128.025 yuan; Conversion premium rate: 5.74%; PE - TTM of the underlying stock: 20.7 [5][31] - Company engages in non - ferrous metal processing, providing materials for emerging industries [31] - In 2024, revenue was 124.161 billion yuan (up 12.36% YoY), net profit attributable to shareholders was 0.462 billion yuan (down 12.29% YoY). In Q1 2025, revenue was 27.285 billion yuan (up 9.89% YoY), net profit attributable to shareholders was 0.151 billion yuan (up 38.55% YoY) [31] - Company highlights: rebound in copper processing, growth in rare - earth permanent magnets, and expansion in electromagnetic flat wire business [32] 4. Aima Convertible Bond (Aima Zhuanzhai) - Bond Rating: AA; 6 - month - end closing price: 123.919 yuan; Conversion premium rate: 37.61%; PE - TTM of the underlying stock: 14.1 [5][40] - Company is a leading player in the electric two - wheeler industry [40] - In 2024, revenue was 21.606 billion yuan (up 2.71% YoY), net profit attributable to shareholders was 1.988 billion yuan (up 5.68% YoY). In Q1 2025, revenue was 6.232 billion yuan (up 25.82% YoY), net profit attributable to shareholders was 0.605 billion yuan (up 25.12% YoY) [40] - Company highlights: subsidy - driven demand, new national standard benefits, and potential margin improvement [41] 5. Xingye Convertible Bond (Xingye Zhuanzhai) - Bond Rating: AAA; 6 - month - end closing price: 124.495 yuan; Conversion premium rate: 13.03%; PE - TTM of the underlying stock: 6.4 [5][52] - Company is a large - scale joint - stock commercial bank with multiple financial licenses [52] - In 2024, revenue was 212.226 billion yuan (up 0.66% YoY), net profit attributable to shareholders was 77.205 billion yuan (up 0.12% YoY). In Q1 2025, revenue was 55.683 billion yuan (down 3.58% YoY), net profit attributable to shareholders was 23.796 billion yuan (down 2.22% YoY) [52] - Company highlights: stable growth in net interest income, stable asset quality, and expanding scale [53] 6. Youfa Convertible Bond (Youfa Zhuanzhai) - Bond Rating: AA; 6 - month - end closing price: 126.782 yuan; Conversion premium rate: 6.47%; PE - TTM of the underlying stock: 14.7 [5][64] - Company is the largest welded steel pipe manufacturer in China [64] - In 2024, revenue was 54.822 billion yuan (down 10.01% YoY), net profit attributable to shareholders was 0.425 billion yuan (down 25.46% YoY). In Q1 2025, revenue was 11.402 billion yuan (up 6.06% YoY), net profit attributable to shareholders was 0.133 billion yuan (up 9680.17% YoY) [64] - Company highlights: national layout, overseas market expansion, and high dividend policy [65] 7. Chongyin Convertible Bond (Chongyin Zhuanzhai) - Bond Rating: AAA; 6 - month - end closing price: 125.956 yuan; Conversion premium rate: 12.15%; PE - TTM of the underlying stock: 7.3 [5][77] - Company is a regional joint - stock commercial bank in the upper reaches of the Yangtze River [77] - In 2024, revenue was 13.679 billion yuan (up 3.54% YoY), net profit attributable to shareholders was 5.117 billion yuan (up 3.8% YoY). In Q1 2025, revenue was 3.581 billion yuan (up 5.3% YoY), net profit attributable to shareholders was 1.624 billion yuan (up 5.33% YoY) [77] - Company highlights: regional economic development opportunities, asset scale growth, and strategic risk management [78] 8. Baidian Convertible Bond (Baidian Zhuanzhai) - Bond Rating: AA; 6 - month - end closing price: 131.325 yuan; Conversion premium rate: 2.85%; PE - TTM of the underlying stock: 24.3 [5][88] - Company is a high - tech enterprise in power distribution equipment [88] - In 2024, revenue was 4.985 billion yuan (up 15.12% YoY), net profit attributable to shareholders was 0.196 billion yuan (up 79.05% YoY). In Q1 2025, revenue was 0.976 billion yuan (up 4.68% YoY), net profit attributable to shareholders was 0.037 billion yuan (up 11.47% YoY) [88] - Company highlights: improving profitability and strong order backlog [89] 9. Huayuan Convertible Bond (Huayuan Zhuanzhai) - Bond Rating: AA -; 6 - month - end closing price: 129.19 yuan; Conversion premium rate: 14.24%; PE - TTM of the underlying stock: 26.3 [5][101] - Company focuses on the vitamin D3 industrial chain [101] - In 2024, revenue was 1.243 billion yuan (up 13.58% YoY), net profit attributable to shareholders was 0.309 billion yuan (up 60.76% YoY). In Q1 2025, revenue was 0.326 billion yuan (down 1.18% YoY), net profit attributable to shareholders was 0.097 billion yuan (up 5.5% YoY) [101] - Company highlights: leading products in the industry, product expansion, and new drug approvals [102] 10. Yushui Convertible Bond (Yushui Zhuanzhai) - Bond Rating: AAA; 6 - month - end closing price: 124.888 yuan; Conversion premium rate: 30.54%; PE - TTM of the underlying stock: 26.6 [5][112] - Company is the largest water supply and drainage enterprise in Chongqing [112] - In 2024, revenue was 6.999 billion yuan (down 3.52% YoY), net profit attributable to shareholders was 0.785 billion yuan (down 27.88% YoY). In Q1 2025, revenue was 1.652 billion yuan (up 8.66% YoY), net profit attributable to shareholders was 0.237 billion yuan (up 28.91% YoY) [112] - Company highlights: stable local business, market expansion, and cost control [113]

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The prices of the main products, Vitamin B1 and B6, remain strong, contributing to profit growth. The company is a significant supplier in the global B vitamin market, holding leading market shares in Vitamin B6 and B1, with a revenue contribution of 78% from B vitamins in 2024. The prices for Vitamin B6 and B1 have shown year-on-year increases of 43.8% and 21.04% respectively in the first half of 2025, driving rapid profit growth [8][5] - The company is expanding its product line with new projects, including Vitamin B5 and Vitamin A, which are expected to enhance its long-term growth potential. The successful launch of these new products could significantly increase the company's market presence [8] - The financial forecast has been slightly adjusted, with expected net profits for 2025, 2026, and 2027 projected at 921 million, 1,063 million, and 1,070 million respectively. The corresponding PE ratios are estimated at 13, 11, and 11 times. The target market value for 2025 is set at 141 billion, indicating a 21% upside potential from the current market value [8][10] Financial Data and Profit Forecast - Total revenue is projected to grow from 2,209 million in 2024 to 2,708 million in 2025, with a year-on-year growth rate of 22.6%. The net profit is expected to increase from 651 million in 2024 to 921 million in 2025, reflecting a growth rate of 41.4% [7][12] - The gross margin is anticipated to improve from 42% in 2024 to 51.1% in 2025, while the return on equity (ROE) is expected to rise from 14.1% to 16.6% during the same period [7][12]

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-020 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 第七届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏 浙江花园生物医药股份有限公司（以下简称"公司"）第七届董事会第十次会议于 2025年6月20日以通讯表决方式召开。会议通知于2025年6月16日以邮件、电子通讯等方 式送达给全体董事。本次会议应参加表决董事9人，实际参加表决董事9人。公司监事、 高管参与了会议。会议符合《中华人民共和国公司法》与《公司章程》的有关规定。 一、审议通过了《关于为全资子公司向银行申请授信额度提供担保的议案》 董事会认为本次担保事项风险可控，不存在损害公司及全体股东利益的情形。具体 内容详见巨潮资讯网（http://www.cninfo.com.cn）上披露的相关公告。 表决结果：同意9票，反对0票，弃权0票。本议案获得通过。 特此公告。 浙江花园生物医药股份有限公司董事会 2025年6月20 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2025-019 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于为全资子公司向银行申请授信额度提供担保的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏 浙江花园生物医药股份有限公司（以下简称"公司"）于2025年6月20日召开的第 七届董事会第十次会议、第七届监事会第七次会议分别审议通过了《关于为全资子公司 向银行申请授信额度提供担保的议案》。现将有关事项公告如下： 一、担保情况概述 为支持公司全资子公司浙江花园药业有限公司（以下简称"花园药业"）业务发展和 经营资金需求，公司同意拟为花园药业向银行申请授信提供总额度合计不超过人民币 30,000万元的连带责任信用担保（实际担保金额、种类、期限等以最终担保合同为准）， 占公司最近一期经审计净资产的9.32%。以上担保额度自董事会审议通过之日起一年内有 效，董事会授权公司董事长在上述额度范围内签署担保事项的相关法律文件。 根据《深圳证券交易所创业板股票上市规则》《公司章程》等相关 ...

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-021 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 第七届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）第七届监事会第七次会议于 2025年6月20日以通讯表决方式召开。会议通知于2025年6月16日以邮件、电子通讯等方式 送达给全体监事。会议应参加表决监事3人，实际参加表决监事3人。会议符合《中华人民 共和国公司法》与《公司章程》的有关规定。 经审议，会议形成如下决议： 一、审议通过了《关于为全资子公司向银行申请授信额度提供担保的议案》 监事会认为公司为全资子公司向银行申请授信额度提供担保的财务风险在公司可控范 围内，有利于增强全资子公司的经营效率和盈利能力。该事项符合相关规定，不存在损害 公司及全体股东利益的情形，同意上述担保事项。 表决结果：3票同意，0票反对，0票弃权。 特此公告。 浙江花园生物医药股份有限公司监事 ...

Core Viewpoint - The global cholesterol market is projected to reach USD 100 million by 2031, with a compound annual growth rate (CAGR) of 4.8% in the coming years [1]. Market Overview - The cholesterol market is primarily driven by its applications in pharmaceuticals, animal feed, and cosmetics, with the pharmaceutical sector being the largest downstream market, accounting for approximately 62.1% of the demand [10][19]. - The NF grade cholesterol dominates the market, holding about 71.3% of the market share [8]. Key Players - Major global cholesterol producers include Zhejiang Huayuan, Dishman, Nippon Fine Chemical, Nanjing Enkai Chemical, and Anhui Tianqi, with the top four manufacturers holding around 86.0% of the market share in 2024 [6][21]. Market Drivers - Strict regulatory standards in pharmaceuticals, animal feed, and cosmetics are influencing the cholesterol market, driving innovation and quality improvements [15]. - The trend towards personalized nutrition and skincare solutions is creating new opportunities for cholesterol applications [16]. - The demand for cholesterol is significantly increasing in emerging economies, particularly in the Asia-Pacific region, driven by urbanization and rising disposable incomes [16]. Market Challenges - The reliance on animal-derived ingredients poses ethical and religious challenges for certain consumer groups, limiting the market [17]. - The negative connotation associated with cholesterol in consumer perception may hinder its application in cosmetics and health products [17]. - The production of cholesterol is sensitive to supply chain disruptions, particularly in animal-derived cholesterol, which can affect pricing and availability [18]. Industry Trends - In the pharmaceutical industry, cholesterol plays a critical role in lipid drug delivery systems, enhancing the bioavailability of active pharmaceutical ingredients [19]. - The increasing demand for high-quality animal products and focus on animal welfare are driving cholesterol's application in animal feed [19]. - In the cosmetics sector, cholesterol is valued for its skin and hair care properties, being widely used in moisturizers and hair treatments [19][20]. Conclusion - The cholesterol market is poised for growth, driven by regulatory compliance, emerging market demand, and evolving consumer preferences towards natural and sustainable products [20].

证券代码：300401 证券简称：花园生物 债券代码：123178 债券简称：花园转债 民生证券股份有限公司（以下简称"民生证券"）编制本报告的内容及信息 来源于浙江花园生物医药股份有限公司（以下简称"花园生物"、"公司"或"发 行人"）对外公布的公开信息披露文件及发行人向民生证券提供的资料。民生证 券按照《公司债券发行与交易管理办法》《公司债券受托管理人执业行为准则》 浙江花园生物医药股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 （中国（上海）自由贸易试验区浦明路 8 号） 二〇二五年六月 重要声明 《可转换公司债券管理办法》等相关规定及与花园生物签订的《受托管理协议》 的约定编制本报告。民生证券对本报告中所包含的从上述文件中引述内容和信息 未进行独立验证，也不就该等引述内容和信息的真实性、准确性和完整性做出任 何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为民生证券所作的承诺 或声明。请投资者独立征询专业机构意见，在任何情况下，投资者不能将本报告 作为投资行 ...

浙江花园生物医药股份有限公司 向不特定对象发行可转换公司债券 2025 年跟踪评级报告 | | | www.lhratings.com 1 声 明 一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日的 独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合资信 基于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对象的事 实陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵循了真 实、客观、公正的原则。鉴于信用评级工作特性及受客观条件影响，本报告 在资料信息获取、评级方法与模型、未来事项预测评估等方面存在局限性。 二、本报告系联合资信接受浙江花园生物医药股份有限公司（以下简称 "该公司"）委托所出具，除因本次评级事项联合资信与该公司构成评级委 托关系外，联合资信、评级人员与该公司不存在任何影响评级行为独立、客 观、公正的关联关系。 联合〔2025〕3369 号 联合资信评估股份有限公司通过对浙江花园生物医药股份有限 公司主体及其相关债券的信用状况进行跟踪分析和评估，确定维持 浙江花园生物医药股份有限公司主体长期信用等级为 AA-，维持"花 园转债"信用等级为 AA-，评级展望为稳 ...